CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.

Elvin Geng, Torsten B. Neilands, Rodolphe Thiébaut, Mwebesa Bwana, Denis Nash, Richard D. Moore, Robin Wood, Djimon Marcel Zannou, Keri N. Althoff, Poh Lian Lim, Jean B. Nachega, Philippa Easterbrook, Andrew Kambugu, Francesca Little, Gertrude Nakigozi, Damalie Nakanjako, Valerian Kiggundu, Patrick Chung Ki Li, David R. Bangsberg, Matthew P. Fox, Hansw Prozesky, Peter W. Hunt, Mary‐Ann Davies, Steven J. Reynolds, Matthias Egger, Constantin T. Yiannoutsos, Eric Vittinghoff, Steven G. Deeks, Jeffrey N. MartinSPIRE 2015 · DOI

Abstract

BACKGROUND Even among HIV-infected patients who fully suppress plasma HIV RNA replication on antiretroviral therapy, genetic (e.g. CCL3L1 copy number), viral (e.g. tropism) and environmental (e.g. chronic exposure to microbial antigens) factors influence CD4 recovery. These factors differ markedly around the world and therefore the expected CD4 recovery during HIV RNA suppression may differ globally. METHODS We evaluated HIV-infected adults from North America, West Africa, East Africa, Southern Africa and Asia starting non-nucleoside reverse transcriptase inhibitorbased regimens containing efavirenz or nevirapine, who achieved at least one HIV RNA level <500/ml in the first year of therapy and observed CD4 changes during HIV RNA suppression. We used a piecewise linear regression to estimate the influence of region of residence on CD4 recovery, adjusting for socio-demographic and clinical characteristics. We observed 28 217 patients from 105 cohorts over 37 825 person-years. RESULTS After adjustment, patients from East Africa showed diminished CD4 recovery as compared with other regions. Three years after antiretroviral therapy initiation, the mean CD4 count for a prototypical patient with a pre-therapy CD4 count of 150/ml was 529/ml [95% confidence interval (CI): 517–541] in North America, 494/ml (95% CI: 429–559) in West Africa, 515/ml (95% CI: 508–522) in Southern Africa, 503/ml (95% CI: 478–528) in Asia and 437/ml (95% CI: 425–449) in East Africa. CONCLUSIONS CD4 recovery during HIV RNA suppression is diminished in East Africa as compared with other regions of the world, and observed differences are large enough to potentially influence clinical outcomes. Epidemiological analyses on a global scale can identify macroscopic effects unobservable at the clinical, national or individual regional level.
BibTeX
@inproceedings{geng2015cd,
  author = {Elvin Geng and Torsten B. Neilands and Rodolphe Thiébaut and Mwebesa Bwana and Denis Nash and Richard D. Moore and Robin Wood and Djimon Marcel Zannou and Keri N. Althoff and Poh Lian Lim and Jean B. Nachega and Philippa Easterbrook and Andrew Kambugu and Francesca Little and Gertrude Nakigozi and Damalie Nakanjako and Valerian Kiggundu and Patrick Chung Ki Li and David R. Bangsberg and Matthew P. Fox and Hansw Prozesky and Peter W. Hunt and Mary‐Ann Davies and Steven J. Reynolds and Matthias Egger and Constantin T. Yiannoutsos and Eric Vittinghoff and Steven G. Deeks and Jeffrey N. Martin},
  title = {{CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.}},
  booktitle = {SPIRE},
  year = {2015},
  doi = {10.7892/boris.68146},
}

Loading related content...

Figure